Hospital de Gran Canaria Dr. Negrin -ko ikertzaileekin lankidetzan egindako argitalpenak (24)

2024

  1. At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. Clinical relevance of timing of assessment of ICU mortality in patients with moderate-to-severe Acute Respiratory Distress Syndrome

    Scientific Reports, Vol. 13, Núm. 1

2022

  1. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

  2. Prognostic implications of comorbidity patterns in critically ill COVID-19 patients: A multicenter, observational study

    The Lancet Regional Health - Europe, Vol. 18

  3. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, Núm. 21

2021

  1. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

    Science immunology, Vol. 6, Núm. 62

  2. Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain

    Critical Care, Vol. 25, Núm. 1

  3. Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia

    ERJ Open Research, Vol. 7, Núm. 1

2020

  1. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

    The Lancet Respiratory Medicine, Vol. 8, Núm. 3, pp. 267-276

  2. Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: Study protocol for a randomized controlled superiority trial

    Trials, Vol. 21, Núm. 1

2018

  1. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study

    Intensive Care Medicine, Vol. 44, Núm. 9, pp. 1470-1482

2017

  1. Improved survival among ICU-hospitalized patients with community-acquired pneumonia by unidentified organisms: a multicenter case–control study

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 1, pp. 123-130

2016

  1. Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions

    Critical Care, Vol. 20, Núm. 1

  2. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome

    Critical Care, Vol. 20, Núm. 1

  3. Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome: Study protocol for a randomized controlled trial

    Trials, Vol. 17, Núm. 1

  4. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis

    Journal of Infection, Vol. 72, Núm. 2, pp. 143-151

2015

  1. Pneumococcal pneumonia coinfection in critically ill patients with influenza a (H1n1) primary viral pneumonia

    Intensive Care Medicine Experimental

2013

  1. Community-acquired Legionella Pneumonia in the intensive care unit: Impact on survival of combined antibiotic therapy

    Medicina Intensiva, Vol. 37, Núm. 5, pp. 320-326

2012

  1. Mortality after surgery in Europe: A 7 day cohort study

    The Lancet, Vol. 380, Núm. 9847, pp. 1059-1065

  2. Recomendaciones del Grupo de Trabajo Enfermedades Infecciosas (GTEI) de la Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC) y el Grupo de Estudio de Infecciones en el Paciente Crítico (GEIPC) de la Sociedad Espanola de Enfermedades Infecciosas y Microbiología clinica (SEIMC) para el diagnóstico y tratamiento de la gripe A/H1N1

    Medicina Intensiva, Vol. 36, Núm. 2, pp. 103-137